Update shared on 14 Nov 2025
Fair value Decreased 6.86%Analysts have lowered their price target for CorMedix from $20.40 to $19.00, citing a more moderate revenue growth outlook and adjusted profit expectations. This comes despite optimism about robust Q3 sales and operational improvements.
Analyst Commentary
Bullish Takeaways
- Bullish analysts highlight the company's robust preliminary Q3 sales, which have exceeded initial expectations and indicate stronger operational execution.
- Improved visibility into near-term operating synergies is seen as a positive sign for continued efficiency gains and profit growth.
- The recent stock pullback has resulted in a more attractive valuation, prompting some analysts to upgrade their recommendations.
- The company's ability to deliver on growth targets despite a challenging environment has led to renewed confidence in its outlook and revised upward ratings.
Bearish Takeaways
- Bearish analysts remain cautious about the sustainability of revenue growth, leading to further lowered profit expectations.
- Concerns remain regarding execution risks as the company works to scale operations and fully realize projected synergies.
- Some analysts believe that, despite positive near-term results, longer-term growth assumptions may still be too optimistic given ongoing industry headwinds.
What's in the News
- CorMedix Inc. announced completion of enrollment for its global Phase III ReSPECT trial, which is evaluating REZZAYO as a treatment intended to prevent invasive fungal diseases in patients undergoing allogeneic blood and marrow transplantation. (Key Developments)
- The company provided fourth quarter 2025 net revenue guidance, projecting a range of $115 to $135 million. (Key Developments)
- Full-year 2025 combined revenues guidance was raised to an estimated range of $325 to $350 million. (Key Developments)
- Susan Blum was appointed as the new Chief Financial Officer of CorMedix, effective August 29, 2025. (Key Developments)
- A special shareholders meeting is scheduled for November 10, 2025, to consider multiple proposals, including amendments to the incentive plan and corporate governance matters. (Key Developments)
Valuation Changes
- The consensus analyst price target has decreased from $20.40 to $19.00, reflecting a more moderate outlook.
- The discount rate has risen slightly from 6.78% to 6.96%.
- Revenue growth expectations have fallen significantly, moving from 52.8% to 28.3%.
- The net profit margin estimate declined from 56.4% to 45.7%.
- The future P/E ratio has increased from 9.24x to 10.79x, indicating a higher valuation relative to projected earnings.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.